Paliperidone 3-month Im Injection Generics - Manufacturers & Suppliers
Trevicta®(EU); Invega Trinza®(US)
| Product/Composition:- | Paliperidone 3-Month IM Injection |
|---|---|
| Strength:- | 273 mg, 410 mg, 546 mg, 819 mg |
| Form:- | Once-3-Month IM Injection |
| Reference Brands:- | Trevicta®(EU); Invega Trinza®(US) |
| MOQ | As per the manufacturer batch size |
| Get Quote Send Enquiry on WhatsApp | |
Paliperidone is an atypical antipsychotic that works by antagonizing dopamine D2 and serotonin 5-HT2A receptors, helping to reduce psychotic symptoms and stabilize mood. The 3-month intramuscular injection is used for the maintenance treatment of schizophrenia in adults who are already stabilized on the 1-month formulation. It ensures consistent therapeutic levels, improves patient adherence, and lowers relapse risk by reducing dosing frequency to four times a year.
Paliperidone 3-month intramuscular injection (brand name: Invega Trinza) is FDA-approved in the United States for the maintenance treatment of schizophrenia in adults who have been stabilized on Invega Sustenna (1-month formulation) for at least four months. In the European Union, it is centrally approved by the EMA with established Risk Management Plans (RMPs) and required pharmacovigilance activities. Regulatory compliance includes GMP-certified long-acting injectable manufacturing, bridging pharmacokinetic and safety data, and documentation for relapse prevention. U.S. labeling includes a boxed warning for elderly patients with dementia-related psychosis. Explore dossier-ready options at Pharmatradz.com — your global B2B pharma hub.